The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Revvity (NYSE: RVTY) and the rest of the research tools & consumables stocks fared in Q4.

The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives.

The 10 research tools & consumables stocks we track reported a satisfactory Q4. As a group, revenues beat analysts’ consensus estimates by 1.2% while next quarter’s revenue guidance was in line.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 19.4% since the latest earnings results.

Revvity (NYSE: RVTY)

Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE: RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure.

Revvity reported revenues of $772.1 million, up 5.8% year on year. This print exceeded analysts’ expectations by 1.1%. Overall, it was a strong quarter for the company with full-year revenue guidance slightly topping analysts’ expectations and a narrow beat of analysts’ organic revenue estimates.

"We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations," said Prahlad Singh, president and chief executive officer of Revvity.

Revvity delivered the weakest full-year guidance update of the whole group. Unsurprisingly, the stock is down 19.6% since reporting and currently trades at $87.53.

Is now the time to buy Revvity? Access our full analysis of the earnings results here, it’s free.

Best Q4: Bio-Techne (NASDAQ: TECH)

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ: TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Bio-Techne reported revenues of $295.9 million, flat year on year, outperforming analysts’ expectations by 2%. The business had a strong quarter with a solid beat of analysts’ organic revenue estimates.

Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 20.3% since reporting. It currently trades at $51.50.

Is now the time to buy Bio-Techne? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: Mettler-Toledo (NYSE: MTD)

With roots dating back to the precision balance innovations of Swiss engineer Erhard Mettler, Mettler-Toledo (NYSE: MTD) manufactures precision weighing instruments, analytical equipment, and product inspection systems used in laboratories, industrial settings, and food retail.

Mettler-Toledo reported revenues of $1.13 billion, up 8.1% year on year, exceeding analysts’ expectations by 2.3%. Still, it was a slower quarter as it posted revenue guidance for next quarter missing analysts’ expectations significantly and a significant miss of analysts’ EPS guidance for next quarter estimates.

As expected, the stock is down 12.7% since the results and currently trades at $1,207.

Read our full analysis of Mettler-Toledo’s results here.

Bruker (NASDAQ: BRKR)

With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ: BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.

Bruker reported revenues of $977.2 million, flat year on year. This result topped analysts’ expectations by 1.4%. Taking a step back, it was a satisfactory quarter as it also logged full-year revenue guidance exceeding analysts’ expectations but a significant miss of analysts’ EPS estimates.

The stock is down 20.5% since reporting and currently trades at $33.75.

Read our full, actionable report on Bruker here, it’s free.

Waters Corporation (NYSE: WAT)

Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters (NYSE: WAT) develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing.

Waters Corporation reported revenues of $932.4 million, down 45.4% year on year. This number was in line with analysts’ expectations. Zooming out, it was a mixed quarter as it also recorded revenue guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ EPS guidance for next quarter estimates.

Waters Corporation had the slowest revenue growth among its peers. The stock is down 21.9% since reporting and currently trades at $297.97.

Read our full, actionable report on Waters Corporation here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.